G
Geron Corporation (GERN)
NMS – Real Time Price. Currency in USD
1.40
+0.01 (0.72%)
At close: May 12, 2026, 4:00 PM EDT
1.42
+0.02 (1.42%)
After-hours: May 12, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
1.40
+0.01 (0.72%)
At close: May 12, 2026, 4:00 PM EDT
1.42
+0.02 (1.42%)
After-hours: May 12, 2026, 7:59 PM EDT
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
| Name | Position |
|---|---|
| Dr. Joseph Emile Eid M.D. | Executive VP of Research & Development and Chief Medical Officer |
| Mr. Ahmed ElNawawi | Executive VP & Chief Commercial Officer |
| Mr. Bryan Ridgell | Senior VP of Portfolio & Project Management and Chief of Staff |
| Mr. Harout Semerjian | CEO, President & Director |
| Mr. Shanthakumar Tyavanagimatt | Senior VP & Chief Technical Officer |
| Mr. Timothy Williams J.D. | Executive VP, Chief Legal Officer & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 10-Q | gern-20260331.htm |
| 2026-04-07 | DEF 14A | gern-20260407.htm |
| 2026-03-26 | 8-K | d192220d8k.htm |
| 2026-03-02 | S-3ASR | d118024ds3asr.htm |
| 2026-02-25 | 8-K | d67820d8k.htm |
| 2026-01-12 | 8-K | gern-20260112.htm |
| 2026-01-06 | 8-K | d88250d8k.htm |
| 2025-12-16 | 8-K | gern-20251210.htm |
| 2025-11-07 | 10-Q | gern-20250930.htm |
| 2025-11-05 | 8-K | gern-20251105.htm |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications |
| Ms. Dawn Schottlandt CFA | Senior Vice President of Investor Relations & Corporate Affairs |
| Ms. Michelle J. Robertson | EVP, CFO, Treasurer and Principal Financial & Accounting Officer |
| Ms. Shannon T. Odam | Executive VP & Chief People Officer |